Holen Sie sich die Stockscreener-App
2.89
2.27%
0.06
Handel nachbörslich:
2.89
Schlusskurs vom Vortag:
$2.83
Offen:
$2.83
24-Stunden-Volumen:
1.75M
Relative Volume:
0.79
Marktkapitalisierung:
$564.41M
Einnahmen:
$7.12M
Nettoeinkommen (Verlust:
$-24.17M
KGV:
-11.87
EPS:
-0.2434
Netto-Cashflow:
$-41.95M
1W Leistung:
+10.47%
1M Leistung:
+18.62%
6M Leistung:
+102.40%
1J Leistung:
+198.38%
1-Tages-Spanne:
$2.80
$2.92
1-Wochen-Bereich:
$2.43
$2.92
52-Wochen-Spanne:
$0.84
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.89 | 552.69M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Roth Capital | Buy |
| 2025-11-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley (OVID) investor files to sell 150,000 shares valued at $420,000 - Stock Titan
Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - Stock Titan
RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - Stock Titan
Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics - Stock Titan
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Ovid Therapeutics (OVID) sees 4.99% beneficial stake reported by Balyasny group - Stock Titan
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
META_TITLE_QUOTE - Yahoo Finance
Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap - Stock Titan
Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings - MarketBeat
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OVID: Advanced pipeline, strong cash runway, and soticlestat monetization drive future growth - TradingView
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OVID: Advanced pipeline, strong cash reserves, and expanded leadership drive long-term growth - TradingView
Ovid Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
OVID Looks 59.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Ovid Therapeutics Inc. Q2 2026: Revenue $0.7M, EPS $(0.08) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Ovid’s OV329 enters Phase 2 study for treatment-resistant focal seizures - Stock Titan
"Biotech in the Balance"Dr. Jeremy Levin, author and Chair of Ovid Therapeutics - MarketScale
Ovid Therapeutics Inc (OVID) News, Articles, Events & Latest Updates - Stocktwits
Ovid Therapeutics Inc (NASDAQ: OVID) Share Price, OVID Stock News, OVID Share Price & Updates - Kalkine
Ovid Therapeutics Inc. (OVID) stock price, news, quote and history - Yahoo Finance Australia
Ovid Therapeutics Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Janus Henderson Group PLC Takes $23.73 Million Position in Ovid Therapeutics $OVID - MarketBeat
Oppenheimer Adjusts Ovid Therapeutics Price Target to $9 From $7, Maintains Outperform Rating - marketscreener.com
Ovid Therapeutics (NASDAQ:OVID) Given New $9.00 Price Target at Oppenheimer - marketbeat.com
Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID - marketbeat.com
Ovid Therapeutics Inc. Revenue Breakdown – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ovid Therapeutics Inc (OVID) Income Statement - TradingKey
OVID|Ovid Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Balance Sheet - TradingKey
Ovid Therapeutics Inc (OVID) Cash Flow - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc. Revenue Breakdown – GETTEX:1OT - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OVID|Ovid Therapeutics Inc|Price:2.330|Chg%:-0.070 - TradingKey
Affinity Asset Advisors LLC Acquires 3,486,318 Shares of Ovid Therapeutics $OVID - marketbeat.com
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ovid Therapeutics Inc-Aktie (OVID) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEVIN JEREMY M | Executive Chairman |
Mar 23 '26 |
Option Exercise |
1.40 |
47,333 |
66,266 |
3,735,048 |
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):